within Pharmacolibrary.Drugs.ATC.R;

model R03CC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.000225,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.156,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007166666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03CC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Salbutamol (also known as albuterol) is a short-acting β2 adrenergic receptor agonist used primarily for the relief and prevention of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is approved for use as a bronchodilator and is commonly administered via inhalation, but can also be given orally or intravenously in certain scenarios.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Morgan, DJ, et al., &amp; Ziccone, SP (1986). Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. <i>British journal of clinical pharmacology</i> 22(5) 587–593. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1986.tb02939.x&quot;>10.1111/j.1365-2125.1986.tb02939.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3790406/&quot;>https://pubmed.ncbi.nlm.nih.gov/3790406</a></p></li><li><p>Tan, WC, &amp; Lee, HS (1991). Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma. <i>European journal of clinical pharmacology</i> 41(5) 495–496. DOI:<a href=&quot;https://doi.org/10.1007/BF00626378&quot;>10.1007/BF00626378</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1761082/&quot;>https://pubmed.ncbi.nlm.nih.gov/1761082</a></p></li><li><p>Anwar, MM, et al., &amp; Zaghary, WA (2015). Salmeterol Xinafoate. <i>Profiles of drug substances, excipients, and related methodology</i> 40 321–369. DOI:<a href=&quot;https://doi.org/10.1016/bs.podrm.2015.02.002&quot;>10.1016/bs.podrm.2015.02.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26051688/&quot;>https://pubmed.ncbi.nlm.nih.gov/26051688</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03CC02;
